Are you Dr. Rifkin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 86 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1800 N Williams St
Ste 200
Denver, CO 80218Phone+1 303-388-4876Fax+1 303-830-8633
Summary
- Dr. Robert Rifkin, MD is an oncologist in Denver, Colorado. He is currently licensed to practice medicine in Colorado and Arizona. He is affiliated with Presbyterian/St. Luke's Medical Center, Rose Medical Center, and AdventHealth Porter.
Education & Training
- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1986 - 1988
- HCA HealthONE/Sky Ridge Medical CenterResidency, Internal Medicine, 1983 - 1986
- University of ColoradoInternship, Internal Medicine, 1982 - 1983
- University of Colorado School of Medicine Anschutz Medical CampusClass of 1982
Certifications & Licensure
- AZ State Medical License 1987 - 2027
- CO State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Start of enrollment: 2004 Mar 01
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation Start of enrollment: 2005 Nov 01
- Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.Sikander Ailawadhi, Hans C Lee, James Omel, Kathleen Toomey, James W Hardin
Blood Cancer Journal. 2024-11-11 - Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectMM Registry.Howard R Terebelo, James Omel, Lynne I Wagner, James W Hardin, Robert M Rifkin
Clinical Lymphoma, Myeloma & Leukemia. 2024-11-06 - The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexametha...Rafat Abonour, Hans C Lee, Robert Rifkin, Sikander Ailawadhi, James Omel
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01
Press Mentions
- Understanding Multiple Myeloma Treatment Patterns and Sequencing with Robert Rifkin, MD, FACPFebruary 6th, 2023
- CU Strategic Plan: Robust Research Goals AheadSeptember 16th, 2021
- US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and ExpositionDecember 2nd, 2020
- Join now to see all
Professional Memberships
- Member